Chitneni SK - Search Results

1

Copper signaling axis as a target for prostate cancer therapeutics.

Safi R, Nelson ER, Chitneni SK, Franz KJ, George DJ, Zalutsky MR, McDonnell DP. Safi R, et al. Among authors: chitneni sk. Cancer Res. 2014 Oct 15;74(20):5819-31. doi: 10.1158/0008-5472.CAN-13-3527. Cancer Res. 2014. PMID: 25320179 Free PMC article.

2

Comparison of the Hypoxia PET Tracer (18)F-EF5 to Immunohistochemical Marker EF5 in 3 Different Human Tumor Xenograft Models.

Chitneni SK, Bida GT, Zalutsky MR, Dewhirst MW. Chitneni SK, et al. J Nucl Med. 2014 Jul;55(7):1192-7. doi: 10.2967/jnumed.114.137448. Epub 2014 May 22. J Nucl Med. 2014. PMID: 24854792 Free PMC article.

3

D-Amino acid peptide residualizing agents bearing N-hydroxysuccinimido- and maleimido-functional groups and their application for trastuzumab radioiodination.

Pruszynski M, Koumarianou E, Vaidyanathan G, Chitneni S, Zalutsky MR. Pruszynski M, et al. Nucl Med Biol. 2015 Jan;42(1):19-27. doi: 10.1016/j.nucmedbio.2014.08.007. Epub 2014 Aug 13. Nucl Med Biol. 2015. PMID: 25240914 Free PMC article.

4

Observations on the Effects of Residualization and Dehalogenation on the Utility of N-Succinimidyl Ester Acylation Agents for Radioiodination of the Internalizing Antibody Trastuzumab.

Chitneni SK, Koumarianou E, Vaidyanathan G, Zalutsky MR. Chitneni SK, et al. Molecules. 2019 Oct 30;24(21):3907. doi: 10.3390/molecules24213907. Molecules. 2019. PMID: 31671554 Free PMC article.

5

Feasibility of Developing Radiotracers for MDM2: Synthesis and Preliminary Evaluation of an ¹⁸F-Labeled Analogue of the MDM2 Inhibitor SP-141.

Chitneni SK, Zhou Z, Watts BE, Zalutsky MR. Chitneni SK, et al. Pharmaceuticals (Basel). 2021 Apr 13;14(4):358. doi: 10.3390/ph14040358. Pharmaceuticals (Basel). 2021. PMID: 33924734 Free PMC article.

6

Fluorine-18 Labeling of the MDM2 Inhibitor RG7388 for PET Imaging: Chemistry and Preliminary Evaluation.

Zhou Z, Zalutsky MR, Chitneni SK. Zhou Z, et al. Among authors: chitneni sk. Mol Pharm. 2021 Oct 4;18(10):3871-3881. doi: 10.1021/acs.molpharmaceut.1c00531. Epub 2021 Sep 15. Mol Pharm. 2021. PMID: 34523337 Free PMC article.

7

Synthesis and Evaluation of a ¹⁸F-Labeled Triazinediamine Analogue for Imaging Mutant IDH1 Expression in Gliomas by PET.

Chitneni SK, Yan H, Zalutsky MR. Chitneni SK, et al. ACS Med Chem Lett. 2018 May 1;9(7):606-611. doi: 10.1021/acsmedchemlett.7b00478. eCollection 2018 Jul 12. ACS Med Chem Lett. 2018. PMID: 30034587 Free PMC article.

8

Stapled peptides as scaffolds for developing radiotracers for intracellular targets: Preliminary evaluation of a radioiodinated MDM2-binding stapled peptide in the SJSA-1 osteosarcoma model.

Zhou Z, Zalutsky MR, Chitneni SK. Zhou Z, et al. Among authors: chitneni sk. Bioorg Med Chem Lett. 2022 Jun 15;66:128725. doi: 10.1016/j.bmcl.2022.128725. Epub 2022 Apr 15. Bioorg Med Chem Lett. 2022. PMID: 35436588 Free PMC article.

9

Molecular imaging of hypoxia.

Chitneni SK, Palmer GM, Zalutsky MR, Dewhirst MW. Chitneni SK, et al. J Nucl Med. 2011 Feb;52(2):165-8. doi: 10.2967/jnumed.110.075663. Epub 2011 Jan 13. J Nucl Med. 2011. PMID: 21233176 Free PMC article. Review.

10

18F-EF5 PET imaging as an early response biomarker for the hypoxia-activated prodrug SN30000 combined with radiation treatment in a non-small cell lung cancer xenograft model.

Chitneni SK, Bida GT, Yuan H, Palmer GM, Hay MP, Melcher T, Wilson WR, Zalutsky MR, Dewhirst MW. Chitneni SK, et al. J Nucl Med. 2013 Aug;54(8):1339-46. doi: 10.2967/jnumed.112.116293. Epub 2013 Jun 5. J Nucl Med. 2013. PMID: 23740105 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

34 results

Search Page